Literature DB >> 1458545

The uses and properties of PEG-linked proteins.

C Delgado1, G E Francis, D Fisher.   

Abstract

Poly(ethylene glycol) (PEG) is a water soluble polymer that when covalently linked to proteins, alters their properties in ways that extend their potential uses. PEG-modified conjugates are being exploited in many different fields. The improved pharmacological performance of PEG-proteins when compared with their unmodified counterparts prompted the development of this type of conjugate as a therapeutic agent. Enzyme deficiencies for which therapy with the native enzyme was inefficient (due to rapid clearance and/or immunological reactions) can now be treated with equivalent PEG-enzymes. PEG-adenosine deaminase has already obtained FDA approval. PEG-modified cytokines have been constructed and, interestingly, one of the conjugates, PEG-modified granulocyte-macrophage colony-stimulating factor, showed dissociation of two biological properties. This novel observation may open new horizons to the application of PEGylation technology. The biotechnology industry has also found PEG-proteins very useful because PEG-enzymes can act as catalysts in organic solvents, thereby opening the possibility of producing desired stereoisomers, as opposed to the racemic mixture usually obtained in classical organic synthesis. Covalent attachment of PEG to proteins requires activation of the hydroxyl terminal group of the polymer with a suitable leaving group that can be displaced by nucleophilic attack of the epsilon-amino terminal of lysine residues (other nucleophilic groups can also interact). Several chemical groups have been exploited to activate PEG, thereby giving rise to a variety of PEG-proteins. Some of these varieties retain part of the activating group as a coupling moiety between PEG and protein and others provide a direct linkage. For each particular application, different coupling methods provide distinct advantages.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458545

Source DB:  PubMed          Journal:  Crit Rev Ther Drug Carrier Syst        ISSN: 0743-4863            Impact factor:   4.889


  56 in total

1.  Unexpected enhancement in biological activity of a GPCR ligand induced by an oligoethylene glycol substituent.

Authors:  Chutima Jiarpinitnun; Laura L Kiessling
Journal:  J Am Chem Soc       Date:  2010-07-07       Impact factor: 15.419

2.  Delivery of neuropeptides from the periphery to the brain: studies with enkephalin.

Authors:  Yoram Shechter; Eli Heldman; Keren Sasson; Tzach Bachar; Mary Popov; Matityahu Fridkin
Journal:  ACS Chem Neurosci       Date:  2010-02-16       Impact factor: 4.418

3.  Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes.

Authors:  N Emanuel; E Kedar; E M Bolotin; N I Smorodinsky; Y Barenholz
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

4.  Viral Nanoparticles: Cancer Vaccines and Immune Modulators.

Authors:  Manlio Fusciello; Erkko Ylösmäki; Vincenzo Cerullo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Fully degradable hydrophilic polyals for protein modification.

Authors:  Alexander Yurkovetskiy; Sungwoon Choi; Alexander Hiller; Mao Yin; Catherine McCusker; Sakina Syed; Alan J Fischman; Mikhail I Papisov
Journal:  Biomacromolecules       Date:  2005 Sep-Oct       Impact factor: 6.988

Review 6.  Development of neuropeptide drugs that cross the blood-brain barrier.

Authors:  Richard D Egleton; Thomas P Davis
Journal:  NeuroRx       Date:  2005-01

7.  Solid-phase synthesis and kinetic characterization of fluorogenic enzyme-degradable hydrogel cross-linkers.

Authors:  Jason A Moss; Shula Stokols; Mark S Hixon; Fawn T Ashley; Jason Y Chang; Kim D Janda
Journal:  Biomacromolecules       Date:  2006-04       Impact factor: 6.988

Review 8.  Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs.

Authors:  Suphiya Parveen; Sanjeeb K Sahoo
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

9.  GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia.

Authors:  M A Nardi; L X Liu; S Karpatkin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

10.  Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease.

Authors:  Stephen Zano; Radhika Malik; Sylvia Szucs; Reuben Matalon; Ronald E Viola
Journal:  Mol Genet Metab       Date:  2010-10-30       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.